肿瘤细胞治疗研究
英文原题：(131)I-labeled engineered hybrid cell membrane biomimetic nanocarrier targets gastric cancer and enhances radioimmunotherapy.
(131)I-labeled engineered hybrid cell membrane biomimetic nanocarrier targets gastric cancer and enhances radioimmunotherapy.
这些发现表明，131 I-Lip RM平台能够实现精准的放射性核素递送，并通过PD-L1阻断增强抗肿瘤免疫，为放射免疫治疗提供了一条有前景的途径。
实现高效的放射性标记和靶向递送对于最大化治疗效果并降低全身毒性至关重要。在此，我们报道了一种基于杂合膜的新型放射性核素递送平台，该杂合膜由脂质体与statherin工程化巨噬细胞膜及胃癌细胞（MFC）膜融合而成。所获得的131 I-lipo@[RAW-MFC]纳米颗粒（131 I-Lip RM）表现出高产率、稳定的放射性标记和同源肿瘤靶向性。利用胃癌模型，我们评估了131 I-Lip RM单独使用以及与抗PD-L1治疗联合使用的生物分布和治疗潜力。131 I-Lip RM显示出良好的药代动力学和高效的肿瘤定位，诱导显著的肿瘤细胞损伤和生长抑制。此外，与单一疗法相比，131 I-Lip RM与抗PD-L1治疗联合可协同增强T细胞介导的免疫应答，促进CD8 + T细胞浸润，并延长生存期。这些发现表明，131 I-Lip RM平台能够实现精确的放射性核素递送，并通过PD-L1阻断增强抗肿瘤免疫，为放射免疫治疗提供了一条有前景的途径。
Achieving efficient radiolabeling and targeted delivery is essential to maximize therapeutic efficacy and reduce systemic toxicity. Herein, we report a novel radionuclide-delivery platform based on hybrid membranes derived from fusing liposome with statherin engineered macrophage membranes and gastric cancer cell (MFC) membranes. The obtained 131 I-lipo@[RAW-MFC] nanoparticles ( 131 I-Lip RM ) exhibit high-yield, stable radiolabeling and homologous tumor targeting. Using a gastric cancer model, we assess the biodistribution and therapeutic potential of 131 I-Lip RM alone and combine with anti-PD-L1 therapy. 131 I-Lip RM show favorable pharmacokinetics and efficient tumor localization, inducing significant tumor cell damage and growth suppression. Furthermore, the combination of 131 I-Lip RM with anti-PD-L1 therapy has synergistically enhanced T cell-mediated immune responses, promoted CD8 + T cell infiltration, and prolonged survival relative to monotherapies. These findings demonstrate that the 131 I-Lip RM platform enables precise radionuclide delivery and potentiates antitumor immunity through PD-L1 blockade, presenting a promising avenue for radio-immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
